Cancer News and Research

Latest Cancer News and Research

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from an ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, AP24534, in patients with resistant and refractory chronic myeloid leukemia (CML). The data confirm strong clinical evidence of hematologic, cytogenetic and molecular anti-leukemia activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with CML, including those with the T315I mutation of the target protein, BCR-ABL.

8 Jun 2010

Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer

Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo.

8 Jun 2010

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

OncoGenex Pharmaceuticals, Inc. today announced final results from a Phase 1 trial. The primary purpose of this trial was to evaluate the safety and tolerability of OGX-427 up to doses of 1000 mg for the treatment of various solid tumors. Patients enrolled had a diagnosis of castrate resistant prostate cancer, breast cancer, ovarian cancer or non-small cell lung cancer.

8 Jun 2010

ZIOPHARM presents positive data from PICASSO Phase II trial for soft tissue sarcoma at 46th ASCO

ZIOPHARM Oncology, Inc. announced today that Dr. Claire Verschraegen of the University of New Mexico, Albuquerque and first author of the abstract, "A phase II randomized controlled trial of palifosfamide plus doxorubicin vs. doxorubicin in patients with soft tissue sarcoma (PICASSO)," (Abstract #10004) presented in an oral session today updated positive data from PICASSO.

8 Jun 2010

Protein p53 becomes activated to control creation of ova and spermatozoids: Study

Protein 53 is very important in protecting against cancer given that it prevents cancer-causing mutations from accumulating and its inactivation is closely linked to the proliferation of tumour cells. UAB lecturer Ignasi Roig participated in the study. Formed by an international research team, the study served to discover that this protein played an unexpected physiological role: it also becomes activated during the formation process of ova and spermatozoids.

8 Jun 2010

Encouraging healthy lifestyle changes helps reduce aging relative's risk of cancer, say experts

Family members can help reduce an aging relative's risk of cancer by encouraging healthy lifestyle changes, according to experts at The University of Texas MD Anderson Cancer Center.

8 Jun 2010

Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL147 (SAR245408), a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

8 Jun 2010

First clinical data for ImmunoGen's IMGN388 anticancer compound presented at ASCO Annual Meeting

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of the first clinical data for the Company's IMGN388 anticancer compound at the 2010 Annual Meeting of the American Society of Clinical Oncology being held in Chicago, IL.

8 Jun 2010

Genetic mutations help predict risk of prostate cancer in younger men: Researchers

Prostate cancer has become more common in younger men, and it's often more aggressive in these men. A new study from researchers at the University of Michigan Comprehensive Cancer Center has found that a series of genetic mutations could help detect this early onset prostate cancer.

8 Jun 2010

Erlotinib can reduce lung cancer death by 26% : Study

Three times as many women with advanced lung cancer were alive and had no progression of their cancer 12 months after taking the drug erlotinib (also known as Tarceva) compared to those who did not receive the drug according to new data being presented at the ASCO1 conference today (Monday).

8 Jun 2010

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Celgene International Sàrl today announced that researchers presented data from an investigator-initiated Phase II study of lenalidomide (REVLIMID) in untreated patients with chronic lymphocytic leukemia at the annual meeting of the American Society of Clinical Oncology.

8 Jun 2010

Cyclacel reports positive interim data from sapacitabine Phase 2 study for myelodysplastic syndromes

Cyclacel Pharmaceuticals, Inc. announced today interim response data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes (MDS) that have failed hypomethylating agents. The data were presented at an oral poster discussion session at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

8 Jun 2010

Tel Aviv University discovers ancient switch in plants that could halt cancer metastasis

Although plants and animals are very different organisms, they share a surprising number of biological mechanisms. A plant biologist at Tel Aviv University says that one of these mechanisms may be the answer for turning off cancer growth in humans.

8 Jun 2010

Lawsuit to be launched over breast cancer gene patent

BRCA1 and BRCA2 are two genes that have been identified to hold a key to women’s susceptibility to get breast or ovarian cancer. Changes also known as mutations in these genes are significant in women who go on to develop breast or ovarian cancer. Melbourne-based company Genetic Technologies Limited (GTL) has the exclusive license from American biotechnology company Myriad Genetics to carry out testing for the genes in Australia. Myriad holds a patent for these genes.

7 Jun 2010

CancerForward: The Foundation for Cancer Survivors launched

The numbers are stark. An astounding three out of every four U.S. families include one family member diagnosed with cancer. Worldwide, 28 million people - more than 12 million people in the U.S. alone - are now living with cancer. While the survivor population continues to grow, few public resources exist to promote the exchange of education and experiential information among survivors.

7 Jun 2010

Hana Biosciences signs Investment Agreement with Warburg Pincus and Deerfield Management

Hana Biosciences Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it has entered into an Investment Agreement with Warburg Pincus and Deerfield Management for the sale of up to $100 million in preferred stock. Warburg Pincus, the lead investor in the financing, is a new investor in Hana, and Deerfield is the company's largest existing shareholder prior to this financing.

7 Jun 2010

Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer

To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.

7 Jun 2010

B2Discovery rallies business leaders in support of excellence in cancer research

The Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al launches B2Discovery, a new research funding model that brings together the private sector and the biomedical research community to help accelerate the discovery of new anti-cancer therapeutics. Inspired by B2ten, which contributed to the success of several Canadian athletes at the Vancouver Winter Olympics, B2Discovery's mission is to partner entrepreneurs with IRIC's cancer investigators to finance novel and promising research projects not currently funded by public granting agencies.

7 Jun 2010

Elekta Neuromag TRIUX system unveiled at Organization of Human Brain Mapping's Annual Meeting

At the Organization of Human Brain Mapping's 16th Annual Meeting (Barcelona, Spain, June 6-10), Elekta unveiled its next generation magnetoencephalography system, Elekta Neuromag TRIUX. A platform that addresses key requirements critical for monitoring normal and abnormal brain activity, Elekta Neuromag TRIUX was designed to operate in virtually any clinical environment – an advance welcomed by the growing number of Elekta Neuromag clinical and research facilities worldwide.

From Elekta 7 Jun 2010

Promising clinical data on CDX-011 in metastatic melanoma presented at ASCO Annual Meeting

Celldex Therapeutics, Inc. today announced the presentation of promising clinical data on CDX-011 in metastatic melanoma at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois. The Phase 2 study has met its primary endpoint and the results support additional studies in this indication.

7 Jun 2010

Cancer News and Research

Latest Cancer News and Research

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

ZIOPHARM presents positive data from PICASSO Phase II trial for soft tissue sarcoma at 46th ASCO

Protein p53 becomes activated to control creation of ova and spermatozoids: Study

Encouraging healthy lifestyle changes helps reduce aging relative's risk of cancer, say experts

Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010

First clinical data for ImmunoGen's IMGN388 anticancer compound presented at ASCO Annual Meeting

Genetic mutations help predict risk of prostate cancer in younger men: Researchers

Erlotinib can reduce lung cancer death by 26% : Study

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Cyclacel reports positive interim data from sapacitabine Phase 2 study for myelodysplastic syndromes

Tel Aviv University discovers ancient switch in plants that could halt cancer metastasis

Lawsuit to be launched over breast cancer gene patent

CancerForward: The Foundation for Cancer Survivors launched

Hana Biosciences signs Investment Agreement with Warburg Pincus and Deerfield Management

Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer

B2Discovery rallies business leaders in support of excellence in cancer research

Elekta Neuromag TRIUX system unveiled at Organization of Human Brain Mapping's Annual Meeting

Promising clinical data on CDX-011 in metastatic melanoma presented at ASCO Annual Meeting

Industry Focus eBook: Oncology eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook: Oncology eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in